T
Alaunos Therapeutics, Inc.
TCRTCIK 0001107421NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
$5.0K
Net Income
$-4.18M
Total Assets
—
Equity
—
Shares Out
24.42M
Op. Cash Flow
$-2.87M
Business
Alaunos Therapeutics, Inc. is a preclinical-stage drug development company focused on discovering and developing therapies for obesity and metabolic disorders. It is developing small molecule oral product candidates, principally ALN1001 and derivatives, designed to alter lipid and energy metabolism without relying on hormonal manipulation. The company’s activities include an obesity small-molecule program and a previously pursued TCR-T cell therapy program that is being wound down. Alaunos targets global obesity markets, particularly the United States, Europe and parts of Asia, and relies on outsourced CMDO/API manufacturing, preclinical studies and potential strategic partnerships for development and distribution.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 5,000 | 10,000 | 5,000 | 3 | 400,000 | |
| Research and development | 1 | 362,000 | 16 | 25 | 50 | |
| General and administrative | 3 | 4 | 12 | 13 | 28 | |
| Total operating expenses | 4 | 5 | 34 | 38 | 78 | |
| Loss from operations | −4 | −5 | −34 | −35 | −78 | |
| Change in fair value of warrant liability | −31,000 | 0 | — | — | — | |
| Other income , net | 80,000 | 133,000 | 1 | 529,000 | −13,000 | |
| Other income (expense), net | 49,000 | 133,000 | −873,000 | −3 | −1 | |
| Net loss | −4 | −5 | −5 | −38 | −79 | |
| Earnings per share, Basic | −2.2 | −2.92 | −21.97 | −2.61 | −0.37 | |
| Earnings per share, Diluted | −2.2 | −2.92 | −21.97 | −2.61 | −0.37 | |
| Weighted average common shares outstanding, basic | 2 | 2 | 2 | 14 | 214 | |
| Weighted average common shares outstanding, diluted | 2 | 2 | 2 | 14 | 214 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1 | 1 | 6 | 39 | 76 | |
| Receivables | 3,000 | 5,000 | 1,000 | 4,000 | 1 | |
| Prepaid expenses and other current assets, current | 600,000 | 2 | 2 | 799,000 | 2 | |
| Total current assets | 2 | 3 | 8 | 54 | 79 | |
| Property and equipment, net | 91,000 | 0 | 2,000 | 8 | 11 | |
| Prepaid expenses and other assets, non current | 887,000 | 0 | — | — | — | |
| Total assets | 3 | 3 | 8 | 65 | 95 | |
| Accounts payable | 613,000 | 516,000 | 616,000 | 1 | 1 | |
| Accrued expenses | 200,000 | 176,000 | 1 | 5 | 6 | |
| Total current liabilities | 813,000 | 692,000 | 2 | 24 | 16 | |
| Total liabilities | 813,000 | 692,000 | 2 | 26 | 37 | |
| Commitments and contingencies (Note 5) | — | — | — | — | — | |
| Common stock $0.001 par value; 50,000,000 shares authorized, 2,349,480 and 1,601,252 shares issued and outstanding at December 31, 2025 and at December 31, 2024, respectively | 2,000 | 2,000 | 2,000 | 16,000 | 216,000 | |
| Additional paid-in capital | 927 | 923 | 922 | 919 | 901 | |
| Accumulated deficit | −925 | −920 | −916 | −881 | −843 | |
| Total stockholders' equity | 2 | 2 | 6 | 39 | 58 | |
| Total liabilities and stockholders' equity | 3 | 3 | 8 | 65 | 95 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 7,000 | 2,000 | 2 | 3 | 3 | |
| Common stock issued for services rendered | 382,000 | 0 | — | — | — | |
| Stock-based compensation | 414,000 | 435,000 | 3 | 4 | 11 | |
| Receivables | 2,000 | −4,000 | 3,000 | 1 | 4 | |
| Prepaid expenses and other current assets | 350,000 | 539,000 | −1 | 867,000 | 9 | |
| Accounts payable | 97,000 | −100,000 | −773,000 | −25,000 | 274,000 | |
| Accrued expenses | 24,000 | −1 | −4 | −668,000 | −11 | |
| Net cash flows from operating activities | −3 | −5 | −30 | −29 | −61 | |
| Purchases of property and equipment | −98,000 | 0 | −197,000 | −216,000 | −3 | |
| Net cash flows from investing activities | −98,000 | 0 | 1 | −193,000 | −3 | |
| Proceeds from the issuance of common stock and pre funded warrants, net of offering costs | 2 | 0 | — | — | — | |
| Proceeds from sale of Series A-1 preferred stock | 500,000 | 0 | — | — | — | |
| Proceeds from sale of Series A-2 preferred stock | 850,000 | 0 | — | — | — | |
| Net cash flows from financing activities | 3 | 0 | −18 | 6 | 26 | |
| Net increase (decrease) in cash, cash equivalents | 294,000 | −5 | −47 | −23 | −39 | |
| Cash paid for interest | 0 | 0 | 2 | 2 | 630,000 | |
| Recognition of warrant liability in connection with the equity line of credit agreement | 178,000 | 0 | — | — | — | |
| Amounts included in accrued expenses and accounts payable related to property and equipment | 67,000 | 0 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro